Deciphera Pharmaceuticals has agreed to merge with ONO Pharmaceutical. As part of this agreement, ONO will purchase all outstanding Deciphera common stock shares at a rate of $25.60 per share in cash. This will be done through a tender offer and subsequent merger with a wholly-owned subsidiary of ONO, bringing the total equity value to $2.4 billion.
Given the upcoming acquisition, Deciphera has announced it will not conduct a first quarter earnings call. However, the firm does intend to submit a Form 10-Q in the usual manner. For additional health-related news, visit rttnews.com.
